RxDoctor Payments Data

Anne Love, NP

Family · Goshen, INNPI 1861465197

Payments from drug & device makers

$1,822in general payments, 2019–2025

Across 101 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$495
  • AbbVie$266
  • Pfizer$212
  • Lilly USA, LLC$167
  • AstraZeneca$115
  • Boehringer Ingelheim$99
  • plus $467 from 13 others

What the payments were for

  • Food & beverage$1,822100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,822 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$81,976
Medicare patients
170
Services billed
1,989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate45$34,481
JardianceEmpagliflozin23$33,549
EliquisApixaban25$30,599
RybelsusSemaglutide15$21,335
MounjaroTirzepatide17$17,975
OzempicSemaglutide15$14,623
FarxigaDapagliflozin Propanediol16$12,092
MyrbetriqMirabegron17$11,119
AbrysvoRsv Vacc, Pref A And Pref B/Pf26$8,255
ShingrixVaricella-Zoster Ge/As01b/Pf23$5,102
SynthroidLevothyroxine Sodium43$3,371
Levocetirizine Dihydrochloride40$2,060
Levothyroxine Sodium237$1,646
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,217
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf17$1,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$212$38,85451 claims
Novo NordiskRybelsus, Ozempic$495$35,95830 claims
Boehringer IngelheimJardiance$99$33,54923 claims
Lilly USA, LLCMounjaro$167$17,97517 claims
AstraZenecaFarxiga$115$12,09216 claims
Astellas Pharma US IncMyrbetriq$17$11,11917 claims
GSKShingrix$17$5,10223 claims
AbbVieSynthroid$266$3,37143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.

Other family in Goshen

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →